Ventripoint Named to 2018 TSX Venture 50 Group of Top Performing Companies
Toronto, Canada – February 22, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce that it has been named to the 2018 TSX Venture 50, a ranking of the top performers on the TSX Venture Exchange over the last year.
"2017 was a historical year for Ventripoint, our employees and shareholders, who have seen the Company increase in market capitalization by 384% and experience share price appreciation of 258%, while trading 206 million shares on the TSX Venture Exchange and 250 million shares on all share exchanges. I would like to take this opportunity to express my gratitude to all of our staff and investors for their continued support and interest in our quest to improve cardiac diagnosis for all,” stated Dr. George Adams, CEO of Ventripoint. “We are excited to celebrate this milestone and are working to deliver even more shareholder value in 2018 and beyond." The TSX Venture 50 ranking is comprised of ten companies from each of the five industry sectors of the TSX Venture Exchange, being: Clean Technology and Life Sciences; Diversified Industries; Mining; Oil & Gas; and Technology. TSX Venture 50 companies are selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. The TSX Venture Exchange has advised the Company that it will be marketing the TSX Venture 50 rankings across Canada and around the world, and will be posting a video profile about Ventripoint. These materials are available at www.tmxmoney.com. About Ventripoint Diagnostics Ltd. Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
|
For further information please contact:
George Adams, CEO
Phone: (519) 803-6937
Email: gadams@ventripoint.com
| ||
